Notable Insider Report: Cynthia Butitta, Chief Operating Officer of Kite Pharma Inc (NASDAQ:KITE) Just Sold Shares

November 29, 2016 - By Clifton Ray

Notable Insider Report: Cynthia Butitta, Chief Operating Officer of Kite Pharma Inc (NASDAQ:KITE) Just Sold Shares

Cynthia Butitta Insider Sell

10,000 shares of Kite Pharma Inc were sold by Cynthia Butitta, the firm’s Chief Operating Officer. The insider shares are valued at exactly $504,015 which has been calculated on the basis of the average transactions stock price ($50.4 for each one share). She also sold 10,000 shares worth approximately $506,467 USD in the last month. This trade was executed on November 28, 2016. A document submitted with the (SEC) and on hand for review here, gives more info for the trade. Cynthia Butitta owns 0.19% of the -company’s market cap or 95,477 shares.

Kite Pharma Inc (NASDAQ:KITE) Ratings Coverage

Out of 10 analysts covering Kite Pharma (NASDAQ:KITE), 9 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 90% are positive. $100 is the highest target while $58 is the lowest. The $82.61 average target is 68.56% above today’s ($49.01) stock price. Kite Pharma has been the topic of 23 analyst reports since August 4, 2015 according to StockzIntelligence Inc. H.C. Wainwright initiated it with “Buy” rating and $78 target price in Monday, November 21 report. FBR Capital maintained it with “Mkt Perform” rating and $72 target price in Tuesday, December 8 report. The rating was initiated by RBC Capital Markets with “Outperform” on Tuesday, February 2. The stock has “Mkt Perform” rating given by FBR Capital on Thursday, September 3. Mizuho maintained the stock with “Buy” rating in Tuesday, May 10 report. The firm has “Buy” rating by Standpoint Research given on Tuesday, August 18. The company was upgraded on Tuesday, August 4 by Vetr. The stock has “Outperform” rating given by Raymond James on Thursday, June 2. FBR Capital maintained the stock with “Mkt Perform” rating in Friday, November 13 report. The rating was maintained by Barclays Capital on Tuesday, August 9 with “Equal-Weight”.

Insitutional Activity: The institutional sentiment increased to 1.63 in 2016 Q2. Its up 0.06, from 1.57 in 2016Q1. The ratio improved, as 23 funds sold all Kite Pharma Inc shares owned while 37 reduced positions. 23 funds bought stakes while 71 increased positions. They now own 36.34 million shares or 0.96% less from 36.69 million shares in 2016Q1.

Viking Global Invsts Lp accumulated 2.53 million shares or 0.54% of the stock. Teacher Retirement Systems Of Texas reported 5,364 shares or 0% of all its holdings. The Ontario – Canada-based Manufacturers Life The has invested 0% in Kite Pharma Inc (NASDAQ:KITE). Geode Management Ltd Liability Com owns 314,073 shares or 0.01% of their US portfolio. Teachers Advisors has invested 0.01% of its portfolio in Kite Pharma Inc (NASDAQ:KITE). Fund Mngmt holds 4,981 shares or 0% of its portfolio. American Group Inc Inc has 0% invested in the company for 22,558 shares. 1832 Asset Management Lp reported 66,600 shares or 0.01% of all its holdings. Blackrock Inc holds 0% or 4,022 shares in its portfolio. Savings Bank Of America De owns 10,233 shares or 0% of their US portfolio. Morgan Stanley has 0% invested in the company for 19,583 shares. Research Global has invested 0.1% of its portfolio in Kite Pharma Inc (NASDAQ:KITE). Pnc Fincl Svcs Gp Incorporated accumulated 0% or 576 shares. Schwab Charles Inv Mgmt has 151,428 shares for 0.01% of their US portfolio. Century reported 300,160 shares or 0.02% of all its holdings.

Insider Transactions: Since May 31, 2016, the stock had 0 insider purchases, and 10 insider sales for $3.36 million net activity. The insider Wiezorek Jeffrey sold $87,362. BUTITTA CYNTHIA M sold 10,000 shares worth $509,350. $812,581 worth of Kite Pharma Inc (NASDAQ:KITE) was sold by DOUMANI ROY.

The stock increased 1.37% or $0.66 during the last trading session, hitting $49.01. About 594,813 shares traded hands. Kite Pharma Inc (NASDAQ:KITE) has risen 2.18% since April 26, 2016 and is uptrending. It has underperformed by 3.08% the S&P500.

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $2.34 billion. The Firm is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. It currently has negative earnings. The Firm offers engineered autologous cell therapy , which is an approach to the treatment of cancer.

According to Zacks Investment Research, “Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of cancer immunotherapy products. The Company is developing a pipeline of eACT-based product candidates for the treatment of solid and hematological malignancies. Kite Pharma, Inc. is headquartered in Santa Monica, California.”

Analysts await Kite Pharma Inc (NASDAQ:KITE) to report earnings on March, 6. They expect $-1.82 earnings per share, down 114.12% or $0.97 from last year’s $-0.85 per share. After $-1.49 actual earnings per share reported by Kite Pharma Inc for the previous quarter, Wall Street now forecasts 22.15% negative EPS growth.

More important recent Kite Pharma Inc (NASDAQ:KITE) news were published by: Fool.com which released: “Do Juno’s Struggles Make Kite Pharma a Buy?” on November 29, 2016, also Marketwatch.com published article titled: “Analysts say Juno’s stock tumbles shouldn’t spill over to Bluebird, Kite ..”, Nasdaq.com published: “First Week of July 2017 Options Trading For Kite Pharma (KITE)” on November 22, 2016. More interesting news about Kite Pharma Inc (NASDAQ:KITE) was released by: Finance.Yahoo.com and their article: “Kite Pharma reports 3Q loss” with publication date: November 09, 2016.

KITE Company Profile

Kite Pharma, Inc., incorporated on June 1, 2009, is a clinical-stage biopharmaceutical company. The Firm is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Firm offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). These modified T cells are designed to recognize and destroy cancer cells. The Firm is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR therapy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>